Kilitch Drugs

Which are the latest news on Kilitch Drugs?

Why is Kilitch Drugs (India) Ltd falling/rising?

As of 04-Aug, Kilitch Drugs (India) Ltd's stock price has risen to Rs 188.10, reflecting a 0.7% increase. This rise is driven by strong relative performance, increased investor participation, and positive trends in moving averages.

As of 04-Aug, Kilitch Drugs (India) Ltd is experiencing a rise in its stock price, currently at Rs 188.10, which reflects an increase of Rs 1.3 or 0.7%. This upward movement can be attributed to several factors. <BR><BR>Firstly, the stock has outperformed its sector by 0.75% today, indicating strong relative performance. Additionally, it reached an intraday high of Rs 194.95, marking a significant increase of 4.36% during the trading session. The stock is also trading above its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, suggesting a positive trend in its price movement.<BR><BR>Moreover, there has been a notable increase in investor participation, with a delivery volume of 1.88k on 03 Aug, which is up by 26.23% compared to the 5-day average. This rise in trading activity can signal growing investor confidence in the stock. Lastly, the stock's liquidity is adequate for trading, as it is based on 2% of the 5-day average traded value, allowing for sufficient trade sizes.<BR><BR>Overall, these factors contribute to the rising stock price of Kilitch Drugs (India) Ltd.

How big is Kilitch Drugs?

As of 10th June, Kilitch Drugs (India) Ltd has a market capitalization of 678.00 Cr and reported net sales of 235.47 Cr and net profit of 30.17 Cr over the latest four quarters.

As of 10th June, <BR><BR>Market Cap: Kilitch Drugs (India) Ltd has a market capitalization of 678.00 Cr, classified as a Micro Cap.<BR><BR>Recent Quarterly Performance: The sum of Net Sales for the latest 4 quarters is 235.47 Cr, while the sum of Net Profit for the same period is 30.17 Cr.<BR><BR>Balance Sheet Snapshot: The reporting period is March 2025, with Shareholder's Funds amounting to 202.33 Cr and Total Assets valued at 309.90 Cr.

Who are in the management team of Kilitch Drugs?

The management team of Kilitch Drugs includes Mukund P Mehta (Managing Director), Bhavin M Mehta and Mira Bhavin Mehta (Whole-time Directors), and several Independent Directors: Hemang Engineer, Murti Vasudev Krishna, and Venkita Subramanian Rajan, along with Pushpa Nyoupane as Company Secretary & Compliance Officer.

The management team of Kilitch Drugs includes the following members:<BR><BR>1. Mukund P Mehta - Managing Director<BR>2. Bhavin M Mehta - Whole-time Director<BR>3. Mira Bhavin Mehta - Whole-time Director<BR>4. Hemang Engineer - Independent Director<BR>5. Murti Vasudev Krishna - Independent Director<BR>6. Venkita Subramanian Rajan - Independent Director<BR>7. Pushpa Nyoupane - Company Secretary & Compliance Officer<BR><BR>If you need more specific information about any of these individuals or their roles, feel free to ask!

Who are the peers of the Kilitch Drugs?

Kilitch Drugs' peers include Sigachi Industries, Anlon Healthcare, Anuh Pharma, and others, with varying management and growth risks. Kilitch Drugs has a 1-year return of -18.31%, better than Sigachi Industries but worse than CCME Global, which leads with a 348.05% return.

Peers: The peers of Kilitch Drugs are Sigachi Indust., Anlon Healthcare, Anuh Pharma, Shree Ganesh Rem, Zim Laboratories, Amanta Healthcar, Jenburkt Pharma, CCME Global, Influx Health, and Remus Pharma.<BR><BR>Quality Snapshot: Excellent management risk is observed at Jenburkt Pharma and Influx Health, while Average management risk is found at Sigachi Indust., Anlon Healthcare, Anuh Pharma, Shree Ganesh Rem, Zim Laboratories, Amanta Healthcar, and CCME Global, and the rest. Below Average management risk is noted for Kilitch Drugs and Remus Pharma. Growth is Excellent at Anlon Healthcare and Kilitch Drugs, while Average growth is seen at Influx Health and the rest, and Below Average growth is observed at Sigachi Indust., Anuh Pharma, Shree Ganesh Rem, Zim Laboratories, Amanta Healthcar, Jenburkt Pharma, CCME Global, and Remus Pharma. Capital Structure is Excellent at Sigachi Indust., Anuh Pharma, Jenburkt Pharma, and Influx Health, Good at Anlon Healthcare and Kilitch Drugs, and Average at Zim Laboratories, while Below Average is noted for Amanta Healthcar.<BR><BR>Return Snapshot: The peer with the highest 1-year return is CCME Global at 348.05%, while the lowest is Sigachi Indust. at -62.71%. Kilitch Drugs has a 1-year return of -18.31%, which is higher than Sigachi Indust. but lower than CCME Global. Additionally, Amanta Healthcar and CCME Global have negative six-month returns.

What does Kilitch Drugs do?

Kilitch Drugs (India) Ltd is a micro-cap pharmaceutical company founded in 1992, specializing in manufacturing and marketing a wide range of pharmaceutical formulations. As of March 2026, it reported net sales of 90 Cr and a net profit of 15 Cr, with a market cap of INR 678 Cr.

Overview:<BR>Kilitch Drugs (India) Ltd is a leading and rapidly growing pharmaceutical company in the micro-cap category, specializing in the manufacturing, supplying, and marketing of a broad range of pharmaceutical formulations in various dosage forms.<BR><BR>History:<BR>Kilitch Drugs (India) Ltd was incorporated in May 1992. The latest quarterly results reported net sales and net profit for the period ending March 2026.<BR><BR>Financial Snapshot:<BR>- Net Sales: 90 Cr (Quarterly Results - Mar 2026)<BR>- Net Profit: 15 Cr (Quarterly Results - Mar 2026)<BR>- Market Cap: INR 678 Cr (Micro Cap)<BR><BR>Key Metrics:<BR>- P/E: 21.00<BR>- Industry P/E: 34<BR>- Dividend Yield: 0.00%<BR>- Debt-Equity: 0.07<BR>- Return on Equity: 10.79%<BR>- Price to Book: 2.36<BR><BR>Contact Details:<BR>Address: C-301/2 MIDC TTC Indl Area, Pawane Village Thane Maharashtra : 400705<BR>Tel: 91-022-27670322/27680913/65144185<BR>Email: info@kilitch.com<BR>Website: http://www.kilitch.in

Should I buy, sell or hold Kilitch Drugs (India) Ltd?

Are Kilitch Drugs (India) Ltd latest results good or bad?

Kilitch Drugs (India) Ltd's latest Q4 FY26 results are strong, with a net profit increase of 227.77% QoQ and revenue growth of 66.51% QoQ, marking the highest revenue in eight quarters. However, investor skepticism persists due to past earnings volatility and the stock's recent underperformance.

Kilitch Drugs (India) Ltd's latest results for Q4 FY26 reflect a strong performance, showcasing significant growth in both revenue and net profit. The company reported a net profit of ₹14.52 crores, marking a remarkable increase of 227.77% quarter-on-quarter (QoQ) and 39.62% year-on-year (YoY). Revenue for the quarter reached ₹89.60 crores, which is a 66.51% increase QoQ and a 46.33% increase YoY. This revenue figure is the highest the company has achieved in at least eight quarters.<BR><BR>Additionally, the operating margin improved to 24.71%, the highest in two years, indicating enhanced operational efficiency. However, despite these impressive quarterly results, the stock has seen a decline of 1.61% following the announcement, which suggests some investor skepticism regarding the sustainability of this performance.<BR><BR>While the quarterly results are strong, the company has experienced considerable volatility in its earnings over the past few quarters, raising concerns about the consistency of its financial performance. Furthermore, the stock has underperformed compared to its peers and the broader market over the past year, which might contribute to the cautious sentiment among investors.<BR><BR>In summary, Kilitch Drugs' latest results are good in terms of growth metrics, but the overall outlook is tempered by concerns over volatility and past performance.

What is the bonus history of Kilitch Drugs?

Kilitch Drugs has announced a 1:1 bonus issue effective March 24, 2026, meaning shareholders will receive an additional share for each share held. The record date and ex-date for this bonus are both March 24, 2026.

Kilitch Drugs has a recent bonus history that includes a 1:1 bonus issue, which is set to take effect on March 24, 2026. This means that for every share held, shareholders will receive an additional share. The record date and ex-date for this bonus issue are both the same, March 24, 2026. If you have any further questions about Kilitch Drugs or its financial activities, feel free to ask!

When is the next results date for Kilitch Drugs (India) Ltd?

The next results date for Kilitch Drugs (India) Ltd is 11 February 2026.

The next results date for Kilitch Drugs (India) Ltd is scheduled for 11 February 2026.

Is Kilitch Drugs technically bullish or bearish?

As of December 4, 2025, the technical trend is mildly bearish, indicated by bearish MACD and moving averages, along with mixed signals from Bollinger Bands and Dow Theory, suggesting weak bearish sentiment in the short to medium term.

As of 4 December 2025, the technical trend has changed from bearish to mildly bearish. The current stance is mildly bearish, driven by several key indicators. The MACD is bearish on the weekly chart and mildly bearish on the monthly chart. Bollinger Bands also indicate a mildly bearish trend on both the weekly and monthly time frames. Moving averages are bearish on the daily chart, while the KST shows a mildly bullish stance weekly but is mildly bearish monthly. Dow Theory presents a mixed view with a mildly bearish signal weekly and a mildly bullish signal monthly. Overall, the combination of these indicators suggests a weak bearish sentiment in the short to medium term.

Is Kilitch Drugs overvalued or undervalued?

As of November 25, 2025, Kilitch Drugs is fairly valued with a PE Ratio of 22.32 and strong growth potential, outperforming peers like Sun Pharma and Divi's Lab, while also delivering a 14.87% return compared to the Sensex's 5.59%.

As of 25 November 2025, the valuation grade for Kilitch Drugs has moved from expensive to fair. The company is currently fairly valued based on its financial metrics. Key ratios include a PE Ratio of 22.32, an EV to EBITDA of 19.36, and a PEG Ratio of 0.41, indicating potential for growth relative to its price. <BR><BR>In comparison to its peers, Kilitch Drugs stands out with its fair valuation against Sun Pharma, which is considered expensive with a PE Ratio of 36.81, and Divi's Lab, which is very expensive at a PE Ratio of 68.57. Additionally, while Kilitch has a ROCE of 10.78% and ROE of 10.38%, it has performed well against the Sensex over the past year, returning 14.87% compared to the Sensex's 5.59%.

How has been the historical performance of Kilitch Drugs?

Kilitch Drugs has experienced significant growth in net sales and profitability, with net sales increasing from INR 53.32 crore in March 2020 to INR 198.32 crore in March 2025, and profit after tax rising from INR 0.84 crore to INR 24.94 crore during the same period. The company's earnings per share also surged from INR 0.54 to INR 16.25, reflecting enhanced shareholder value.

Answer:<BR>Kilitch Drugs has shown significant growth in its historical performance, particularly in net sales and profitability over the past several years.<BR><BR>Breakdown:<BR>Kilitch Drugs' net sales have consistently increased from INR 53.32 crore in March 2020 to INR 198.32 crore in March 2025, reflecting a strong upward trend. Total operating income followed a similar trajectory, reaching INR 198.32 crore in March 2025, up from INR 82.49 crore in March 2019. The company's operating profit (PBDIT) also saw substantial growth, rising from INR 4.33 crore in March 2020 to INR 42.63 crore in March 2025, indicating improved operational efficiency. Profit before tax increased from INR 1.61 crore in March 2020 to INR 34.47 crore in March 2025, while profit after tax surged from INR 0.84 crore to INR 24.94 crore in the same period. The earnings per share (EPS) rose significantly from INR 0.54 in March 2020 to INR 16.25 in March 2025, showcasing enhanced shareholder value. On the balance sheet, total assets grew from INR 141.86 crore in March 2020 to INR 309.90 crore in March 2025, with total liabilities also increasing, primarily due to long-term borrowings that began in March 2024. The cash flow from operating activities improved to INR 17 crore in March 2025, compared to a negative cash flow in March 2024, indicating a recovery in operational cash generation. Overall, Kilitch Drugs has demonstrated robust growth in sales, profits, and asset base over the years.

Who are the top shareholders of the Kilitch Drugs?

The top shareholder of Kilitch Drugs is Kilitch Company (Pharma) Limited, holding 41.22%. Other notable shareholders include Dipak Kanayalal Shah with 3.11% and individual investors collectively owning 25.57%.

The top shareholders of Kilitch Drugs are primarily the promoters, with Kilitch Company (Pharma) Limited holding the largest stake at 41.22%. There are no pledged promoter holdings, and mutual funds and foreign institutional investors do not currently hold any shares in the company. Among public shareholders, Dipak Kanayalal Shah is the most significant, holding 3.11%. Additionally, individual investors collectively hold 25.57% of the shares.

Has Kilitch Drugs declared dividend?

Kilitch Drugs has declared a 5% dividend, amounting to 0.5 per share, with an ex-date of September 20, 2019. Despite this, the dividend yield is 0%, as the company has not provided ongoing dividends, though it has shown strong price returns over the years.

Kilitch Drugs has declared a dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 5%<BR>- Amount per share: 0.5<BR>- Ex-date: 20 Sep 19<BR><BR>Dividend Yield: 0%<BR><BR>Total Returns by Period:<BR>In the last 6 months, the price return was 31.1%, with a dividend return of 0%, resulting in a total return of 31.1%.<BR><BR>For the 1-year period, the price return was 36.77%, with a dividend return of 0%, leading to a total return of 36.77%.<BR><BR>Over the 2-year period, the price return was 110.95%, with a dividend return of 0%, resulting in a total return of 110.95%.<BR><BR>In the 3-year period, the price return was 160.59%, with a dividend return of 0%, leading to a total return of 160.59%.<BR><BR>For the 4-year period, the price return was 171.11%, with a dividend return of 0%, resulting in a total return of 171.11%.<BR><BR>In the last 5 years, the price return was 342.78%, with a dividend return of 0%, leading to a total return of 342.78%.<BR><BR>Overall, Kilitch Drugs has declared a dividend, but the dividend yield remains at 0%. The company has shown substantial price returns over the years, indicating strong performance despite the lack of ongoing dividends.